21:55 , Dec 1, 2017 |  BC Week In Review  |  Company News

Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline. Medicines Co. will receive $270 million up front,...
00:16 , Nov 30, 2017 |  BC Extra  |  Company News

Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline. Medicines Co. will receive $270 million up front,...
21:40 , Oct 27, 2017 |  BC Week In Review  |  Company News

Medicines Co. to cut workforce, focus on inclisiran

In its 3Q17 earnings announcement, The Medicines Co. (NASDAQ:MDCO) said it would reduce headcount to fewer than 60 employees to focus on developing inclisiran (PCSK9si). On Oct. 25, the company said it plans to start...
22:24 , Oct 25, 2017 |  BC Extra  |  Company News

Medicines Co. to cut workforce, focus on inclisiran

In its 3Q17 earnings announcement, The Medicines Co. (NASDAQ:MDCO) said it would reduce headcount to fewer than 60 employees to focus on developing inclisiran (PCSK9si). Next week, the company plans to start a Phase III...
01:25 , May 10, 2016 |  BC Extra  |  Company News

Medicines Co. selling some CV assets to Chiesi

The Medicines Co. (NASDAQ:MDCO) is selling its non-core cardiovascular assets to Chiesi Farmaceutici S.p.A. (Parma, Italy). The deal includes Cleviprex clevidipine, Kengreal cangrelor and the company's rights to ready to use argatroban. It does not...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

1Q approvals

1Q approvals CompanyApprovalAlexion Pharmaceuticals Inc. (NASDAQ:ALXN)Japan approves Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D)Amgen Inc. (NASDAQ:AMGN)Japan approves Repatha evolocumab to treat familial hypercholesterolemia or hypercholesterolemia in patients at high risk of cardiovascular events...
07:00 , Mar 21, 2016 |  BC Week In Review  |  Clinical News

Kangio bivalirudin regulatory update

FDA issued a complete response letter to Eagle for an NDA for anticoagulant Kangio bivalirudin, a ready-to-use formulation of Angiomax bivalirudin from The Medicines Co. (NASDAQ:MDCO, Parsippany, N.J). The agency is requesting “further...
00:42 , Mar 19, 2016 |  BC Extra  |  Company News

Eagle slides after FDA rejects anticoagulant Kangio

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) sank $10.18 (19%) to $43.50 on Friday after FDA issued a complete response letter for an NDA for anticoagulant Kangio bivalirudin, a ready-to-use formulation of Angiomax bivalirudin from The Medicines Co....
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

Hospira, Medicines Co. sales and marketing update

Hospira launched in the U.S. a generic version of Angiomax bivalirudin from The Medicines Co. The generic is for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA),...